SmithKline's reformulated Dyazide
Executive Summary
Results from additional clinical studies requested by FDA on SmithKline's improved Dyazide were submitted to the agency in mid-September as part of a supplemental NDA filed in 1985. Bolar's generic version of Dyazide was approved by FDA on Aug. 21.